Clinical Trials
23 trialsNCT07603791 2026-05-22
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 2 Not yet recruiting
NCT07309276 2026-05-18
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
NCT07230405 2026-05-12
A Phase II Study of SKB571 in Patients With Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT07308106 2026-05-11
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT07296809 2026-05-08
SKB500 Combinations in Patients With Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06897579 2026-04-28
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT06809946 2026-03-30
DEFLECT I
University Medical Center Groningen
Phase 2 Not yet recruiting
NCT05816252 2026-01-27
MK-2870-003
Klus Pharma Inc.
Phase 2 Active not recruiting
NCT06496490 2025-11-20
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT07076095 2025-07-21
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 2 Not yet recruiting
NCT06962865 2025-07-16
A Phase â…¡ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06199895 2025-06-03
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
Tongji Hospital
Phase 2 Recruiting
NCT06514027 2024-07-23
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
BeBetter Med Inc
Phase 2 Not yet recruiting
NCT06045767 2024-06-03
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer
Tel Aviv Medical Center
Phase 2 Not yet recruiting
NCT06299371 2024-03-07
Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations
Liaoning Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT02872701 2023-03-24
OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
On Target Laboratories, LLC
Phase 2 Completed
NCT05782426 2023-03-23
Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT04571632 2022-09-14
Luscid
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT04167774 2019-11-22
Compass-001
Sun Yat-sen University
Phase 2 Unknown
NCT03351842 2017-12-19
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT01660399 2015-12-22
Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02223611 2014-08-22
S1VSNP
Hebei Medical University Fourth Hospital
Phase 2 Unknown
NCT00918281 2014-06-09
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
Phase 2 Completed